5 Likewise, research published in 2024 indicates that semaglutide approximately doubles NAION risk, albeit with a very low absolute incidence, emphasizing the need for clinicians and patients to remain vigilant
In these patients, the excess of dietary methionine might even reduce their hyperhomocysteinemia by favoring homocysteine catabolism (Loehrer et al, 1996)
Dhirani D, Shahid A, Mumtaz H
In such cases, the peptide should be labeled as a research chemical or reference material, and not intended for human use
Patients with poorly controlled depression, active suicidal ideation, or recent medication changes may not be ideal candidates for initiating weight loss therapy until their mental health is stabilized
Mild temporary symptoms may include: Redness at injection site Light nausea Slight fatigue or headache during adjustment phase Not recommended for individuals with active cancers or certain metabolic conditions our physicians will evaluate your history during consultation